21st Annual bioProcessUK Conference 2024

Caelan Anderson

Co-Founder and CEO, Tolemy Bio

Caelan Anderson is the co-founder and CEO of Tolemy Bio, driven by a deep passion for understanding and characterizing complex systems. With expertise in Physics, Data Science, and Software Engineering, he leverages these skills to solve intricate challenges in biotechnology. Caelan holds a degree in Physics from the University of Melbourne and began his career in defence technology, developing self-healing communication networks for the Australian Department of Defence.

At the cultivated meat startup Vow, he led the development of autonomous robotic systems for cell culture, built genome-scale metabolic models, and created advanced algorithms to accelerate cell-line development.

Before founding Tolemy Bio, Caelan successfully ran Apollo, a software company delivering innovative solutions across Europe and the Asia-Pacific region. At Tolemy, he now drives company strategy and operations, leading the development of cutting-edge technology while fostering a dynamic team.

---

Steve Bates

Chief Executive Officer

Steve Bates is the CEO of the UK Bioindustry Association, the UK’s Trade Association for innovative life science companies with over 550 members. Steve is the visible face of the vibrant UK life sciences industry to government and media. He serves on the UK Government’s Life Sciences Council and the UK Biosecurity Leadership Council. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. He is active member and former chair the International Council of Biotech Associations and has been a board member of EuropaBio since 2015.

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He is a driving force behind the scale up agenda, spearheading policy agenda to unlock UK pension fund capital into productive UK growth in life sciences. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before joining the BIA in 2012, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair working on NHS reform and the Northern Ireland peace process. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

: stevebatesuk
: @SteveBatesUK

---

Alice Brown

Chief Scientific Officer, Purespring Therapeutics Ltd

Prior to joining Purespring, Alice was a Senior Director in the department of Cell Therapy Innovation at Takeda Pharmaceuticals following the acquisition by Takeda of GammaDelta Therapeutics in 2021, where Alice had held the roles of VP Research and, before that, VP Gene Engineering.

At GammaDelta Alice built and lead the research team and was responsible for developing multiple cell therapy programs from discovery through to completion of pre-clinical development. Alice joined GammaDelta from PsiOxus Therapeutics where she was the Director of Biology.

Alice holds a degree and PhD in Biochemistry from the University of Bristol and carried out her post-doctoral research in Immunology at Imperial College London.

---

Roz Campion

Director, Office for Life Sciences

Rosalind is the Director of the Office for Life Sciences in the UK Government. OLS is a joint unit which is part of the Department for Health and Social Care and the Department for Science Innovation and Technology. OLS brings together government, the NHS, academia and industry to drive improvements in patient outcomes and economic growth through its support for the life sciences sector. Roz joined OLS in November 2021.

 Rosalind began her career as a solicitor working in the City before moving into government. Within government she has extensive experience of working on social and economic policy issues, with roles spanning the setting up and running of the Sentencing Council, to leadership roles in the Cabinet Office, the Home Office and in the Department of International Trade. She spent a number of years working as a diplomat in Washington DC and Tokyo.

---

Simon Chandler

Chief Executive Officer, Rinri Therapeutics

Simon is the CEO of Rinri Therapeutics. Having been involved with the company since its inception, he has collaborated closely with the scientific founder and is responsible for the company's strategy, operations and financing. With a career spanning several blue-chip biotechnology and pharmaceutical development companies, Simon possesses extensive knowledge and experience in the life science and biotech sectors.

Before joining Rinri, Simon was an Investment Director at IP Group, a deep-tech venture capital fund. In this role, he specialized in early-stage investment and venture building, creating new companies based on world-class science. His experience at IP Group provided him with broad exposure to the life science market, including therapeutics, devices, tools, synthetic biology, and AI.

Simon is a firm believer in Rinri's technology having taken it from its academic roots to clinical trials within the next 12 months. He sees Rinri as being at the forefront of hearing loss therapeutic development and is confident in its potential to make a significant global impact on patients, healthcare, and the broader economy.

Simon holds a first-class BSc (Hons) in Biology from the University of Leeds, a PhD in Molecular Biology and Biochemistry from the University of York, and an MBA from Durham University

---

Chris Davies

Project Engineer, Cell & Gene Therapy Catapult

I am a project engineer currently working for Cell and Gene Therapy Catapult (CGTC), where we are delivering site wide redevelopment to support collaborators with large scale cell and gene therapy research and development. The site was previously manufacturing animal vaccines. The redevelopment works looks to realise the potential of the site as a GMP manufacturing innovation hub to support the growing bioprocessing industry within the UK. I have worked within the cell and gene therapy GMP manufacturing space since 2017. Previous roles have included the design and build of gene therapy manufacturing facilities, maintenance engineering support for gene therapy production as well as process engineering support and project management. This has given me a broad understanding of the engineering support companies require to be able to safely manufacture these novel medicines that aim to cure diseases. Prior to my current appointment I have delivered clean room construction project management across the manufacturing sector for space, bioprocessing, imaging, micro electronic and technology sectors. 

---

Bill Dawson

SVP, Global Head of Biologics and Devices, GlaxoSmithKline

Bill is a senior leader with over 25 years’ experience in the Vaccines, BioPharma, Pharmaceutical and Clinical Research (CRO) industries. He was recently appointed as Chair of the Medicines Manufacturing Industry Partnership and has held a number of executive roles across different countries, leading operations and in Global Quality roles working to FDA/MHRA/EMEA/WHO/ROW standards. Following his role as Global Head of Quality for GSK Vaccines, Bill now leads GSK’s Biologics and Devices Manufacturing Network delivering specialty and respiratory products to hundreds of millions of patients globally. Bill is the global sponsor of DEI for the GSK Global Supply Chain and has a strong people, performance and quality-compliance focus; driving growth through culture change and a passion for innovation and simplification.

---

Kit Erlebach

Senior Director, Engineering & BIA MAC Chair, FUJIFILM Diosynth Biotechnologies

Kit is responsible for Engineering and EHS at FUJIFILM Diosynth Biotechnologies in the UK. Kit has also worked as a Biochemical Engineer for 20 years and holds a Lean Six Sigma leader Master Black Belt qualification. He has applied LSS to quality, engineering and manufacturing in the course of leading laboratory construction projects totalling more than £100M. Kit has a first degree from Nottingham University in Chemical Engineering and a PhD from Cambridge University in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. He an MBA from the Open University as part of the ATAC programme.

---

Suzy Farid

University College London

Suzanne joined UCL as a Lecturer in 2001. She obtained her Bachelor’s and Ph.D. degrees in Biochemical Engineering from UCL.

---

Brendan Fish

Director of Biologics & RNA Centre of Excellence, CPI

No bio provided

---

Jonathan Furbey-Taylor

Global Sustainability Project Leader, AstraZeneca UK Ltd

Jonathan Furbey-Taylor is a Global Sustainability Project Leader at AstraZeneca, implementing changes across the business that deliver AstraZeneca’s sustainability ambitions.  This includes leading the global rollout of data visualisation from Smart Metering data, as well as leading the transition of AstraZeneca’s  global fleet to 100% EV where technically possible.  Prior to this role, Jonathan has worked in project management and leadership roles across various industries including Retail, Consumer Services and E-Commerce.

---

Nick Gardiner

What does your role at BIA involve?
Nick is responsible for overseeing the BIA’s operations, ensuring that all activities are professionally delivered to the highest standard and providing an organisation-wide operational perspective to and support for, activities and projects. He has specific responsibility for office management/facilities; financial systems/processes and credit control; the people, skills and talent workstream; company secretariat; human resources and IT/telecoms.
Previous experience & achievements
Nick has extensive industry and not-for-profit management experience. Prior to this role, he ran the Clinical Laboratory Division of Lab21. This involved providing specialist laboratory services to the healthcare, pharmaceutical and clinical trials markets. In that role, Nick had management responsibility for all operations, income, laboratory and customer services and client liaison across the Group. He also has specific and extensive experience of diagnostic testing within the HIV and HCV disease areas. This was gained through building Delphic Diagnostics into a one-stop shop for clinicians, enabling more effective patient monitoring and subsequent treatment options. Nick also has broad management experience within the not-for-profit and charity sector, working for a trade body representing and building the profile of the business communication industry and prior to that working for the world’s oldest active society devoted to natural history.
If you could invite any scientist or entrepreneur to dinner, who would it be?
Alfred Russel Wallace, a naturalist, explorer, geographer, anthropologist, biologist and illustrator, independently conceived the theory of evolution through natural selection. He travelled the world and I would imagine had some excellent stories to tell.

: nick-gardiner-47a41818

---

Laura Griffiths

Innovation Lead, Innovate UK

Laura joined the Transforming Medicines Manufacturing Team at Innovate UK in January 2021. As an Innovation Lead, Laura manages government funded projects, and engages with different organisations within the sector, to understand manufacturing challenges and the innovation needed to grow the UK’s medicines manufacturing economy. Laura is passionate that by working together, sharing knowledge, and driving innovation, the medicines manufacturing community can have a greater overall impact. Prior to joining Innovate UK Laura spent 7 years working for Eli Lilly and Elanco, as a technical and manufacturing leader, and 3 years working for a biologics contract manufacturing organisation, Eden Biodesign (currently Pharmaron). Laura has a BSc (Hons) in Biochemistry, and a PhD in Biotechnology, both from The University of Manchester. Laura’s technical scientific background is within upstream bioprocessing, with expertise in both mammalian and microbial cultures.

---

David Gruber

Ipsen Biopharm Ltd

David joined IPSEN in April 2017 and is currently Senior Director, Bioprocess Sciences.  He brings in excess of 20 years’ experience in bioprocess development, tech transfer and cGMP manufacturing for biopharmaceutical products.  Prior to joining Ipsen David spent 10 years working at MedImmune and 5 years at Xenova developing manufacturing processes for early and late phase clinical products.  David’s expertise spans platform and novel technology development, process / product understanding and application of multivariate analysis.  More recently his keen interest in sustainability has seen him engage in Ipsen’s sustainability programs, supporting both Engineering and Procurement activities.  In 2023 David volunteered to lead the Manufacturing Advisory Committee’s Sustainability working group. 

---

Jonathan Haigh

Head of UK Sites, FUJIFILM Diosynth Biotechnologies

Jonathan Haigh has been active in the biopharmaceutical industry for almost twenty years, working in both the Life Science technology vendor and end-user sectors, holding positions in both the US and UK. He completed a Ph.D. in antibody purification from the University of Cambridge, and an MBA from Durham University Business School. Jonathan has fulfilled a number of global technical, management and leadership roles encompassing biopharmaceutical innovation, process development, GMP operations, and merger & acquisition activities.

Jonathan has worked for FUJIFILM Diosynth Biotechnologies for the last twelve years in roles of increasing responsibility. He previously acted as Vice President of Process Development, leading a team of over 350 process scientists and engineers across Mammalian, Microbial and Advanced Therapy modalities. He currently holds the role of Head of UK Sites, leading all aspects of the business across three UK sites. Jonathan holds a number of patents and publications pertinent to the bioprocessing field.

---

Oli Hall

CTO and Co-Founder , New Wave Biotech

Oli Hall is the CTO and Co-Founder of New Wave Biotech. They trained at Imperial with 10 years experience in software development, including as the lead engineer at LabGenius who built their software team and launched the foundations of their AI-powered drug discovery platform.

---

Janet Hemingway

Professor of Tropical Medicine, Liverpool School of Tropical Medicine

Janet Hemingway is Professor of Tropical Medicine at the Liverpool School of Tropical Medicine (LSTM) and Founding Director of the Infection Innovation Consortium (iiCON). Responding to the growing challenge of infectious diseases, antimicrobial resistance, and emerging pandemics, iiCON brings together academic, industry, and clinical partners in a £170 million programme to transform the discovery and supply of much-needed anti-infectives and accelerate their journey to market.

She is a senior technical advisor on Neglected Tropical Diseases for the Bill and Melinda Gates Foundation and has been PI on projects in excess of £370 million including the BMGF funded Innovative Vector Control Consortium, the ERDF funded Formulations programme and the BMGF funded Visceral Leishmaniasis Elimination programme.

She is a Past President of the Royal Society of Tropical Medicine and Hygiene.

Professor Hemingway was appointed the Director of LSTM in 2001 and stepped down on 1st January 2019. She was awarded a CBE for services to the Control of Tropical Disease Vectors in 2012.

---

Nige Hilton

Head of Manufacturing and Site Head, Liverpool , CSL Seqirus

Nige joined CSL Seqirus in January 2019 with 30 years Pharma experience gained in Site Operations, engineering, product development and industrialisation. 

Nige spent his early career working for AstraZeneca delivering production plant expansion and routine operations for a sterile parental product, Zoladex.  He then joined Sanofi’s inhalation development and manufacturing site where he held positions as Head of Device development, Head of Engineering and Head of Manufacturing Operations. During this time, he played a major role in shaping strategy, restructuring the business and delivering a site turnaround.  This included leading the successful industrialisation and routine supply of third-party products as part of a transition to becoming a CMO under new ownership.

Nige is a chartered Engineer and holds a Bachelor of Science degree in Mechanical Engineering.  He is a formally trained six sigma black belt and experienced lean practitioner.

---

Caryn Hughes

Partnerships & Innovation Lead, The Pandemic Institute

Prior to joining The Pandemic Institute, Caryn was Manager of the Doctoral Training Hub at the University of Glasgow, leading a multi-institutional team responsible for providing end-to-end management and administration for numerous UKRI-funded Centres for Doctoral Training (CDTs). At this time, Caryn also served as Coordinator for the CDT in Future Ultrasonic Engineering in partnership with Strathclyde University. Before this, Caryn worked as a Business Development Manager for an EPSRC and SFI CDT between the University of Glasgow, Queen’s University Belfast and the Irish Photonic Integration Centre.

Caryn’s former research background was based on spectral pathology for disease-state diagnostics, working as a PhD student and Research Associate at the Cancer Research UK Manchester Institute, the Analytical and Medical Vibrational Spectroscopy Group at the Manchester Institute of Biotechnology, and as a Visiting Researcher at the Spectral Analytics Laboratory at the University of Strathclyde.

---

Esther Karunakaran

Senior Lecturer/Associate Professor in Biological Engineering , The University of Sheffield

Esther Karunakaran is a Senior Lecturer/Associate Professor in Biological Engineering at the University of Sheffield. She is a molecular microbiologist with research interests in applying fundamental knowledge of microbial physiology and biofilm behaviour to overcome challenges in bioprocessing, environmental engineering and healthcare sectors. Together with her colleague, Dr. J. M. MacInnes, she is working towards delivering an innovative, compact, high performance bioreactor for the bioproduction of a wide variety of chemicals. They are exploring the possibility of setting up a spin-out company, Spironix, to manufacture and distribute these innovative bioreactors.

---

Rachel Kelly

Global Sustainability Project Leader, AstraZeneca UK Ltd

Rachel Kelly is a Global Sustainability Project Leader within AstraZeneca, leading a diverse range of projects across AstraZeneca’s sustainability program. This includes leading the Operations workstream for Access to Healthcare, as well as leading the Scope 3 program to ensure delivery of key attributes of AstraZeneca’s Ambition Zero Carbon targets. Within her current role, Rachel is also responsible for managing the early careers and talent team within Global SHE (Safety, Health & Environment). Prior to this role, Rachel has spent 10 years at the site in Macclesfield working in various Supply Chain leadership roles.

---

Swapnil Khadke

Co-Founder and CEO, IntelligenceQ

Dr. Swapnil Khadke is the Co-Founder and CEO of IntelligenceQ, where he leads a passionate effort towards transforming sustainable medicine manufacturing through advanced AI solutions. With over a decade of experience spanning pharmaceutical development, product management, and research, Dr. Khadke has been at the forefront of integrating AI into health sciences, always focusing on the practical needs of scientists and manufacturers. Under his leadership, IntelligenceQ's platform, GyaniMed™, bridges complex scientific data across research, design, and validation stages, offering scientists sophisticated yet accessible tools to advance medicine development effectively.

Previously, Dr. Khadke held pivotal roles in multiple early-stage TechBio startups, where he spearheaded projects involving micro-implant development for real-time health monitoring and innovative drug delivery systems targeting age-related disorders. He has a rich academic background with a Ph.D. in Health Sciences from Aston University and a Master’s in Pharmaceutics and Drug Design from UCL, complemented by various awards in scientific excellence from prestigious institutions like GSK and UKICRS.

Driven by a belief that AI, when applied thoughtfully, can dramatically enhance efficiency and collaboration, Dr. Khadke continues to advocate for accessible and cost-effective AI solutions that support the critical work of pharmaceutical scientists, ultimately accelerating the delivery of life-saving treatments.

 

---

Rosie Lindup

Policy and Public Affairs Manager, BioIndustry Association

Previously, Rosie worked as a Senior Research Consultant at a Westminster-based public affairs agency, where she supported clients from a range of sectors, including pharmaceuticals, technology and financial services. Prior to that, Rosie worked as a Management Consultant at KPMG, where she assisted on financial and regulatory projects with large corporate clients. She has a BA in Human, Social and Political Sciences from the University of Cambridge.

---

Joe Mawby

REACH Industries

As a Business Development Manager at Reach Industries, I focus on the international expansion of Lumi, driving the growth of our Visual Intelligence and automation platform in new markets. My background in engineering, gives me a solid technical foundation as I work closely with our development teams and external partners to identify opportunities and develop strategies that scale our technology globally. By combining my technical expertise with a passion for building meaningful relationships, I ensure that Lumi’s AI-driven solutions reach scientists and businesses worldwide, helping them accelerate their work and drive innovation.

---

Ian McCubbin

Chair of RoslinCT, Chair of Cell and Gene Therapy Catapult

Chair of RoslinCT and Chair of Cell and Gene Therapy Catapult; Chair of Manufacturing Advisory Group for IUK Industrial Challenge Fund; Member of the UK Government Vaccines Task Force. Ian retired from his role as SVP North America, Japan & Global Pharma Supply, GSK in April 2017. He joined GSK in 2006, his second spell with the company and was responsible for 17 factories and 7,000 employees globally whose role within GSK was to supply the New Product pipeline and the majority of GSK's pharmaceutical sales. Ian chaired the Advanced Therapy Manufacturing Task Force originally co-chaired with George Freeman, Minister for Life Sciences and the group published its Action Plan to 'anchor' commercial scale manufacturing in the UK. The Action Plan has subsequently been adopted in full as part of the Life Sciences Industrial Strategy. He led the manufacturing work stream of the UK Vaccines Task Force between March 2020 and May 2021. Ian is a pharmacist with 40 years of experience in the Pharmaceutical industry working for GSK, Merck Generics and IVAX. His core capability is in the field of manufacturing and supply chain leadership and new product introduction. His passion is cell and gene therapies due to their transformational medical benefits and the opportunity they create for UK economic benefit.

---

James Nicholls

Lead Project Engineer, Ipsen Biopharm Ltd

James joined Ipsen in October 2023 and is currently a Lead Project Engineer working on the site’s capital investment projects including sustainability driven initiatives. 

James is new to the pharmaceutical sector having previously spent 10 years delivering projects in the food and drink industry following completion of a MEng in Chemical Engineering. 

---

Andrew Olaye

General Manager, UK and Ireland and Head of EMEA Market Access, Orchard Therapeutics

Andrew Olaye is General Manager, UK and Ireland as well as the Head of EMEA Market Access at Orchard Therapeutics. He has over 15 years of experience in commercial management,  pricing and reimbursement, market access, health economics, encompassing various roles of increasing responsibilities at Grunenthal, BioMarin, Vertex Pharmaceuticals and Orchard Therapeutics. During this time, he has successfully commercialised several innovative therapies for rare disease (including cell and gene therapies) across Europe and the Middle East.

---

Angela Osborne

Founder and CEO, eXmoor Pharma Concepts

No bio provided

---

Stella Peace

Executive Director for Healthy Living and Agriculture, Innovate UK

Dr Stella Peace is a purpose driven leader who is passionate about the role of science and technology to create transformational innovations. Stella’s experiences span academic research, international business and more recently UKRI where she is Executive Director for Healthy Living and Agriculture at Innovate UK Before joining Innovate UK, Stella had over twenty-five years’ experience as an international business leader in the consumer goods industry and Life Sciences sector. Throughout her career she has led R&D teams to deliver local, regional and global business innovations for iconic, household brands that that drive growth. Stella’s academic background is in Chemistry with a PhD in Polymer Chemistry. She is a keen runner and passionate foodie.

---

Andrea Pearson

Operations Engineering Manager, Fujifilm Diosynth Biotechnologies

Andrea is the Operations Engineering Manager at FUJIFILM Diosynth Biotechnologies in Billingham, UK and has responsibility for all maintenance on site. She is a Chartered Chemical Engineer who has worked for over 16 years in the Petrochemical and now Biotechnology industries. Her career has included Operations Management of Upper Tier COMAH sites, Manufacturing Excellence Improvement Projects and Turnaround Management. In 2021 she moved to FUJIFILM Diosynth Biotechnologies, firstly working as Technical Operations Manager for the Mammalian Cell Culture Manufacturing assets and then into Maintenance Management. Andrea was named one of the WES Top 50 Women in Engineering 2021 and is passionate about encouraging women into STEM careers and striving towards more sustainable manufacturing.

---

Mark Proctor

Vice President and Site General Manager, AstraZeneca

Mark Proctor is the Vice President and Site GM for AstraZeneca UK Operations in Macclesfield (UK), where over 1500 colleagues perform a range of manufacturing across oral solid dose formulation, parenterals, sterile manufacturing, and packing for global distribution to over 117 markets worldwide. Prior to this role, Mark has held several senior roles across biopharmaceutical development, quality, supply chain, vaccine technical operations, and site leadership. In addition to his role at AstraZeneca, Mark is a lay-council member and trustee for the University of Liverpool – established in 1881 as the first red-brick University and part of the internationally renowned Russell Group. Mark is a Fellow of the Institute of Chemical Engineers, holds a Master’s degree in Biochemical Engineering (UCL), an Executive MBA (Bayes Business School, London), and Certificate in Company Direction (IoD). He was recognized nationally with a CBE in the 2021 Queen’s Birthday Honours in recognition of his services to the Covid-19 response. Mark is also the AstraZeneca representative on MMIP.

---

Alan Robertson

Head of Operational Engineering, Medicines Manufacturing Innovation Centre

Alan Robertson is the Head of Operational Engineering at CPI's Medicines Manufacturing Innovation Centre. With a diverse background spanning military service and pharmaceutical engineering, Alan brings a wealth of experience to his role. Alan served 23 years in the Royal Navy as a Weapons Engineering Mechanic (Ordnance) specializing in submarines. His career culminated as a Facilities Manager and Instructor at the Royal Navy Strategic Systems School in Faslane, where he delivered training on the Trident Weapon System using a state-of-the-art £50M simulator. Following his military service, Alan transitioned to the medical devices and pharmaceutical industry. Over 15 years, he held various positions in GMP facilities as Engineering Manager and Facilities Manager. Prior to joining CPI in May 2021, Alan served as the Engineering/Facilities Manager at Curia in Glasgow, where he successfully managed three major cleanroom facility overhauls. Outside of work, he is an avid fly fisher and whisky enthusiast.

---

Leo Chi U Seak

CEO and Lead Scientist, Genenet Technology Limited

Leo Chi U Seak is the CEO and Lead scientist of GeneNet Technology (UK), after getting his PhD (neuroscience) from the University of Cambridge.He co-founded GeneNet in the hope of helping the biotech industry to screen and produce drugs more efficiently. Leo is currently the project manager of Genenet’s CHO cell bioproduction (Funded by InnovateUK) and bioplastic bioproduction (Funded by ERDF) projects. Leo is also the inventor of the machine learning based genetic circuits used in the company, and he also has experience in leading research projects in the International Genetically Engineered Machine (iGEM) teams for years and has published multiple biotech papers.

---

Alex Ward

Co-Founder and CSO, Tolemy Bio

Alex Ward is the co-founder and CSO of Tolemy Bio. Alex has a background in Cellular and Systems Biology, spanning diverse areas of academic and industry science, from heart disease to MRI Physics. He is driven by bringing together computational tools and novel technologies to answer complex biological questions.

Since completing his PhD at the University of Bristol, he has undertaken post-doctoral work at the Victor Chang Cardiac Research Institute in Sydney, Australia, specialising in congenital heart disease functional genomics. After which, he joined the cultivated meat startup, Vow, leading teams in large-scale tissue engineering and cell culture media development. At Vow, he was responsible for driving the development of cell culture media for diverse and exotic cell-lines, using bioinformatics, high-throughput suspension process development and big data analytics.

Since then, Alex has embarked on a journey into entrepreneurship, founding the boutique analytics consulting company, Arta Bioanalytics, and, more recently, Tolemy Bio. At Tolemy, Alex is focussed on business development, commercial activity and scientific team and infrastructure.

---

Stephen Ward

Chief Manufacturing Officer, Cell and Gene Therapy Catapult

No bio provided

---